Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Phase 1 dosing is expected to finish by the end of 2025
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Upgrades 2025 full-year CDMO sales and margin outlook
Subscribe To Our Newsletter & Stay Updated
